European Commission Approves Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone (EPd) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma

On August 27, 2019

Notice: ob_end_flush(): failed to send buffer of zlib output compression (0) in /home/biznews/public_html/wp-includes/functions.php on line 5219

Related Post

Boeing, NASA Complete First Starliner Space Station Flight Test

Northrop Grumman Australia Announces Tech Showcase Winners

IQVIA CFO Ron Bruehlman to Speak at Jefferies Healthcare Conference on June 10, 2022